Portal de Periódicos da CAPES

Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase

2021; Massachusetts Medical Society; Volume: 385; Issue: 19 Linguagem: Inglês

10.1056/nejmoa2113017

1533-4406

Hana M. El Sahly, Lindsey R. Baden, Brandon Essink, Susanne Doblecki‐Lewis, Judith M. Martin, Evan J. Anderson, Thomas Campbell, Jesse L. Clark, Lisa A. Jackson, Carl J. Fichtenbaum, Marcus Zervos, Bruce Rankin, Frank Eder, Gregory Feldman, C Kennelly, Laurie J. Han-Conrad, Michael Levin, Kathleen M. Neuzil, Lawrence Corey, Peter B. Gilbert, Holly Janes, Dean Follmann, Mary Marovich, Laura Polakowski, John R. Mascola, Julie E. Ledgerwood, Barney S. Graham, Allison August, Heather Clouting, Weiping Deng, Shu Han, Brett Leav, Deb Manzo, Rolando Pajón, F. Schödel, Joanne E. Tomassini, Haiyu Zhou, Jacqueline M. Miller,

Animal Virus Infections Studies

At interim analysis in a phase 3, observer-blinded, placebo-controlled clinical trial, the mRNA-1273 vaccine showed 94.1% efficacy in preventing coronavirus disease 2019 (Covid-19). After emergency use of the vaccine was authorized, the protocol was amended to include an open-label phase. Final analyses of efficacy and safety data from the blinded phase of the trial are reported.